Silexion Therapeutics’ SIL204 emerges as a potential game-changer in KRAS-driven cancer treatment

Silexion Therapeutics (NASDAQ: SLXN) has taken a major step forward in oncology research, unveiling new preclinical data on its experimental therapy, SIL204. The clinical-stage biotechnology company has reported that SIL204 demonstrated significant efficacy in suppressing both primary tumors and metastatic spread in pancreatic cancer models. Given that KRAS mutations drive more than 90% of pancr